Lack of effects of fibrinogen degradation products on specific binding of [3H]spiroperidol and [3H]ADTN.
No effect of fibrinogen degradation products on specific binding of [3H]spiroperidol and [3H]ADTN was observed. Low molecular weight peptides derived from fibrinogen degradation by plasmin (FDP) increase the motor activity of rats [7] augment apomorphine- and amphetamine-induced stereotypy and diminish haloperidol catalepsy [2]. It has been suggested that FDP interact with central dopamine receptor [2]. Taking the above considerations into account it was decided to investigate the effect of FDP on specific binding of [3H] spiroperidol and 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene ([3H]ADTN).
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D002090:Butyrophenones / Q000378:metabolism*; D004298:Dopamine / Q000494:pharmacology; D005338:Fibrin Fibrinogen Degradation Products / Q000502:physiology*; D066298:In Vitro Techniques; D008297:Male; D008970:Molecular Weight; D009281:Naphthalenes / Q000378:metabolism*; D051381:Rats; D011954:Receptors, Dopamine / Q000502:physiology; D013134:Spiperone / Q000378:metabolism*; D013764:Tetrahydronaphthalenes / Q000378:metabolism*
D002090:Butyrophenones; D005338:Fibrin Fibrinogen Degradation Products; D009281:Naphthalenes; D011954:Receptors, Dopamine; D013764:Tetrahydronaphthalenes; D013134:Spiperone; C011639:ADTN; D001058:Apomorphine; D004298:Dopamine